dr oz glp 1 Dr. Oz: Cheaper GLP-1 drugs coming for millions of Americans DR. OZ: ELIGIBLE MEDICARE RECIPIENTS

Moran, Claus Aagaard Nielsen, Mikkel Due Petersen, Lars Nygaard, David rsted, Christian Poulsen, Tina Secher Rasmussen, and Else Marie Agger (Novo Nordisk A/S, Denmark) for review of and input to the manuscript, and to Alexander Jones, PhD, CMPP TM and Sola Neunie, MSc, CMPP TM from AXON Communications (supported by Novo Nordisk) for writing assisstance

Industry coverage has highlighted growing investor attention toward emerging obesity and metabolic therapies, further reinforcing the importance of reliable sourcing partners

Mary Colman has over 24 years of experience in integrative metabolic care and whole-food supplementation using Standard Process products

Ozempic is not currently FDA-approved for fatty liver disease, but some doctors prescribe it off-label for high-risk patients